Sensei Biotherapeutics to Participate in the H.C. Wainwright 27th Annual Global Investment Conference
Rhea-AI Summary
Sensei Biotherapeutics (NASDAQ:SNSE), a clinical stage biotech company developing next-generation cancer therapeutics, announced its participation in the upcoming H.C. Wainwright 27th Annual Global Investment Conference.
CEO John Celebi will conduct one-on-one investor meetings on September 8, 2025. The company's on-demand corporate presentation will be available starting September 5, 2025, at 7:00 a.m. ET. Investors can access the webcast replay in the Investors section of Sensei's website for approximately 90 days after the event.
Positive
- None.
Negative
- None.
News Market Reaction – SNSE
In the Sep 3 session, SNSE gained 10.57%, reflecting a significant positive market reaction. Argus tracked a peak move of +10.1% during that session. Our momentum scanner triggered 4 alerts that day, indicating moderate trading interest and price volatility.
Data tracked by StockTitan Argus on the day of publication.
AI-generated analysis. How Rhea-AI works. Not financial advice.
BOSTON, Sept. 03, 2025 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), a clinical stage biotechnology company focused on the discovery and development of next-generation therapeutics for cancer patients, today announced that John Celebi, President and Chief Executive Officer, will participate in 1x1 investor meetings at the H.C. Wainwright 27th Annual Global Investment Conference on Monday, September 8, 2025.
An on-demand corporate presentation will be available here on September 5, 2025, at 7:00 a.m. ET. A replay of the webcast will be available in the Investors section of the Sensei website for approximately 90 days following the event.
About Sensei Biotherapeutics
Sensei Biotherapeutics (Nasdaq: SNSE) is a clinical stage biotechnology company focused on the discovery and development of next-generation therapeutics for cancer patients. Through its TMAb™ (Tumor Microenvironment Activated biologics) platform, Sensei develops conditionally active therapeutics designed to disable immunosuppressive signals or activate immunostimulatory signals selectively in the tumor microenvironment to unleash T cells against tumors. Sensei’s lead product candidate is solnerstotug, a conditionally active antibody designed to block the V-domain Ig suppressor of T cell activation (VISTA) checkpoint selectively within the low pH tumor microenvironment, where VISTA acts as a suppressor of T cells by binding the receptor PSGL-1. For more information, please visit www.senseibio.com, and follow the company on X @SenseiBio and LinkedIn.
Investor and Media Contact:
Joyce Allaire
LifeSci Advisors
Jallaire@lifesciadvisors.com
